{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"40"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"11"}],"units":"Participants"}],"description":"ORR is presented in this outcome measure as number of responders. Responders were those who had complete remission and partial remission. Lugano classification (Cheson et al., 2014) and refinement (Cheson et al., 2016) were used for tumor response assessment for lymphomas by computed tomography (CT)-based criteria and complete metabolic response (CMR) or partial metabolic response (PMR) by positron emission tomography (PET-CT) based criteria were used for evaluation. Lymphomas evaluated by Lugano Classification include aggressive B-cell lymphoma (ABCL), Hodgkin's lymphoma (HL), Non-Hodgkin's lymphoma, indolent B-cell lymphoma (IBCL), peripheral T-cell lymphoma (PTCL), and part of T-cell lymphoma (TCL).","groups":[{"description":"Participants with ABCL who received study drug in Part 2.","id":"OG000","title":"Part 2: Aggressive B-cell Lymphoma (ABCL)"},{"description":"Participants with HL who received study drug in Part 2.","id":"OG001","title":"Part 2: Hodgkin Lymphoma (HL)"},{"description":"Participants with IBCL who received study drug in Part 2.","id":"OG002","title":"Part 2: Indolent B-cell Lymphoma (IBCL)"},{"description":"Participants with cHL who received nivolumab combination in Part 2.","id":"OG003","title":"Part 2: Classical Hodgkin's Lymphoma (cHL)"},{"description":"Participants with CD20-positive malignancies who received rituximab combination in Part 2.","id":"OG004","title":"Part 2: CD20-positive Malignancies"},{"description":"Participants with PTCL who received study drug in Parts 2 and 3.","id":"OG005","title":"Parts 2 and 3: Peripheral T-cell Lymphoma (PTCL)"},{"description":"Participants with TCL who received study drug and response assessment by Lugano Classification (Cheson 2014/2016) in Parts 2 and 3.","id":"OG006","title":"Parts 2 and 3: T-cell Lymphoma (TCL)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set included all participants who received at least 1 dose of study treatment. \"Number of Participants Analyzed\" refers to participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)","title":"Part 2 and 3: Overall Response Rate (ORR) - Lugano Classification (Cheson 2014) and Refinement (Cheson 2016) Disease Indications and Nivolumab/Rituximab Combinations","type":"SECONDARY","unitOfMeasure":"Participants"}